Type A viral hepatitis is endemic in the Israel Defence Forces (IDF). Hepatitis B infections, however, account for about 5-10% of all cases of hepatitis. During the two decades before 1970 large-scale epidemics occurred every three to four years. During such epidemics, the annual incidence of hepatitis in the IDF exceeded 10 per 1000 and reached as high as 15 per thousand.
The last such outbreak took place in . Between 1970 2-1963 1965 1967 1969 1971 1973 1975 1977 1979 (years) Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis East Asia4 and in Swedish UN soldiers serving in the Middle East.5 Nevertheless, the value of pre-exposure immune serum globulin administered to an indigenous population living in a hyperendemic area is a different issue and would depend largely on the extent of the susceptible population-that is, those without prior antibodies to hepatitis A virus.
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The aim of this study was to examine whether pre-exposure prophylaxis with immune serum globulin, administered within the framework of a controlled field trial to identified high risk populations in the IDF, would provide an effective preventive measure. Specifically, the objectives were to measure the degree of protection afforded to those immunised, the duration of protection, and the feasibility of using widespread pre-exposure, rather than postexposure, immunisation in high-risk populations in the IDF.
Two high-risk groups, new recruits and regular field units in whom the incidence of infectious hepatitis is substantially higher than the rest of the army population, were selected for intervention. Cases among recruits in whom the first reported symptoms of disease occurred fewer than 10 days after induction were excluded from analysis. Cases that were hepatitis B surface antigen positive were also excluded.
When any study subject developed hepatitis, a decision to administer immune serum globulin-that is, postexposure prophylaxis-to non-immunised personnel in the same unit was taken, based on the same criteria governing the postexposure prophylactic administration of immune serum globulin in the IDF over the past years.
Statistical testing for the difference in occurrence of viral hepatitis in the recruits allocated to the intervention and control groups was by the log rank method.a Withdrawals-that is, early release from service-were considered to have occurred equally in both groups and were not entered into the calculations. Pre-exposure prophylaxis with immune serum globulin for prevention of viral hepatitis is that described above in whom the immunisation status was uncertain.) Until about 40 weeks after intervention the immunised group appears to enjoy an increasing advantage. At this point, however, the slope of the control group increases sharply and begins to converge on the intervention group. At roughly one year after entry into the trial, the curves again diverge. Between seven and 12 months the incidence rates are almost identical-0-82 per 1000 in the immunised and 0 72 in the non-immunised. Between 13 and 18 months the rates are, somewhat surprisingly, 0-64 per 1000 and 1-52 per 1000 respectively (58% protection). Over the seven to 18 month period the rates are 1-46 and 2-24 per thousand respectively (35% protection), and over the entire 18 months 1-64 per thousand in the immunised and 3.28 in the non-immunised (50% protection). The protection afforded by the vaccine in both sexes was similar (data not shown). The results as presented are somewhat conservative because the numerator in the intervention group includes one case whose immunisation status was doubtful, but the denominator excludes 781 subjects who were allocated to the intervention group but were not immunised. In table 2 the incidence rates are calculated also when the initial allocation of study subjects to the intervention and control groups is maintained. The differences in incidence between the two groups are increased.
Applying the log rank test (table 3) , the immunised enjoyed a statistically significant advantage in the first six months (p = 0-01), the first nine months (p = 0-001), and the first 18 months (p = 0-013), while in the first 12 months the p value exceeded the 0-05 level. When the comparison is made between the intervention and control groups as originally allocated (table 3), the statistical significance of the differences is enhanced.
When the 18-month follow-up period is subdivided into three consecutive six-month periods, the first six months shows a significant difference between the two groups (see above), seven to 12 months shows no difference, while between 13 and 18 months there are significantly fewer cases among those immunised than in the non-immunised group (p = 0.043).
The difference in occurrence between the two study groups is maintained over the entire 1 8-month study period.
Discussion
It is apparent that immune serum globulin exerted a strong protective effect over the six-month follow-up period. During the six months, only two cases of "immunisation failure" occurred; of these, one probably did not receive immune serum globulin. The benefit of pre-exposure prophylaxis in this trial in the context of the widespread use of postexposure immune serum globulin in the IDF lay in preventing the first case or cases in an outbreak, because subsequent cases would usually be prevented by postexposure immune serum globulin. Thus the protective efficacy of immune serum globulin in the present trial in preventing type A hepatitis (or rather, non-B hepatitis) over six months (83%) is a conservative estimate because additional cases in the non-immunised subjects were prevented by postexposure prophylaxis applied after the appearance of a case or cases depending on the circumstances and the probability of transmission.
Routine pre-exposure prophylaxis has been used successfully by Swedish UN troops (a very susceptible population) in the Middle East since the 1960s. In contrast to the indigenous Israeli population of military recruits, only 2-4% of Swedish troops in Cyprus (average age 24 9 years) had antibodies to hepatitis A virus.5 Kluge9 reported in 1963 that ISG prophylaxis provided 98% protection of Swedish UN troops in the Gaza strip. In contrast, a very large-scale randomised US Army study in Korea In the months immediately before inception of the study monthly incidence rates for hepatitis for the entire IDF were high compared with the expectation based on previous years. Continued high ranges were predicted based on the patterns of previous years. Indeed, the expectation was for a hyperendemic year. During the study, however, incidence of disease among the non-immunised dropped well below levels predicted for the season of year. The proportion of total disease in the IDF generated by the non-immunised inductees was very low in comparison with rates in inductees in previous years (data not presented). This reduction in incidence may be unrelated to the intervention. The possibility exists, however, that immunisation of part of the population may affect disease patterns in the non-immunised, and that the unexpectedly low rates seen in the non-immunised inductees is a herd-immunity type effect. A test of this hypothesis would have required an additional totally non-immunised but equally susceptible and equally exposed control group.
One would expect that if herd immunity occurred it would be more apparent during the first six months of follow-up than at 13-18 months when protection by immune serum globulin should have waned. The 13-18 month period is exactly parallel by season to the first six-month period of exposure but is one year later. The incidence in the non-immunised inductees (1 04 per thousand) is somewhat lower than at 13-18 months (1.52 per thousand). Although the difference is not statistically significant, the direction of the difference hints at a possible herd-immunity effect. This is supported by the prior knowledge that incidence rates are as a rule substantially higher in the IDF during the first six months of service, which includes basic training, than thereafter. This uncontrolled "evidence," however, is only suggestive.
Regarding duration of protection, the difference in incidence between the non-immunised and immunised increased to 40 weeks of follow-up. It has generally been considered that a pre-exposure dose of 5 ml of immune serum globulin confers protection for up to six months and hence the recommendation of the United States Public Health Service to repeat Jeremy D Kark injections every four to six months.2 This does not take into account varying concentrations of antibody to hepatitis A in immune serum globulin. The prolonged protection seen in the present study (40 weeks) is consistent with the experience of Stokes et al,'4 who observed protection for five to nine months in institutions for the mentally retarded. Duration of protection may be a function of hepatitis A virus antibody titre of immune serum globulin, and it would appear that even very low residual titres of antibody to hepatitis A are protective, considering that the half-life of IgG is estimated to be a mean of about three weeks.
Between 10 and 12 months of follow-up there was a steeper increase in incidence among the immunised that the non-immunised, indicating loss of protection afforded by immune serum globulin (and possibly even hinting at increased susceptibility in the immunised group, although this could also be a result of chance variation). This possibility relates to the potential problem of immune serum globulin at least theoretically interfering with the immune response in those infected with hepatitis A virus, by neutralising the virus, resulting in lack of passive-active immunity.
Thus when the passive protection of immune serum globulin wears off, subjects would remain susceptible to infection. Thus reinfection and disease would simply be delayed until later unless immune serum globulin was repeated periodically. The follow-up until 18 months does not support this conclusion, but it remains a possibility. There are little published data relating to this issue.
It has been suggested that passive-active immunisation will result only if the hepatitis A virus antibody titre is sufficient to suppress clinical expression of infection, but insufficient to neutralise the virus and prevent seroconversion. Somewhat surprisingly, during the last six months of follow-up, from 13 to 18 months, the incidence in those who did not receive immune serum globulin was considerably higher than in the immunised group, indicating the possibility of prolonged protection. No explanation could be found for this peculiar finding. There do not appear to be similar descriptions published. This may well be a chance finding resulting from an arbitrary subdivision into time periods, although these divisions were made before the data were viewed. Over the seven to 18 month period the level of protection was 35%, and over the entire 18-month period the protection was 50% as contrasted with 83% over the first six months.
The cost of the intervention in terms of personnel and materials must be contrasted with the outlays due to hospitalisation, service-days lost, and postexposure immunisation. These data cannot be presented; however, a preliminary cost-benefit analysis has indicated that pre-exposure immunisation was economic and provided excellent returns on investment, even when the incidence of disease in the non-immunised study population was unusually low.
Hoofnagle21 has recently recommended that pre-exposure prophylaxis of type A hepatitis should probably be used only for travellers to endemic areas and for handlers of newly imported primates. In the context of the IDF, however, we believe that pre-exposure prophylaxis in high-risk populations is an improvement of the previous policy of postexposure immune serum globulin protection, and in addition to reducing endemic morbidity in inductees it reduces the probability of larger localised outbreaks that from time to time are not prevented by postexposure immune serum globulin due to late administration.
After this trial, policy with regard to the use of immune serum globulin in the IDF was modified and routine single immunisation with immune serum globulin instituted for all new inductees during that part of the year when hepatitis morbidity is high. This provides protection during the first months of service that are associated with raised rates. After the concommitant trial in field units,6 annual pre-exposure prophylaxis was also introduced into this population. Surveillance of the incidence of hepatitis in the IDF over the two years after the policy change proved most encouraging. Incidence rates dropped appreciably in the entire IDF to a low point of 1*25 per thousand in 1979 (fig 1) .
Immunisation failures in the two intervention populations were exceedingly rare.
As many of the inductees already carry antibody to hepatitis A virus on the day of induction into the army, it is obvious that giving immune serum globulin to all as done in this trial is both unnecessary and wasteful. Identification of hepatitis A virus negative and thus susceptible subjects would be most beneficial. Nevertheless, the techniques presently available to measure hepatitis A antibodies and the infrastructure needed to draw and process blood samples and retrieve the information are too expensive to justify routine screening of all 17-18 year olds before induction. Until a vaccine that induces active immunity against hepatitis A virus is available, it will be necessary to consider strategies for a more selective approach to pre-exposure prevention of viral hepatitis in the IDF.
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